nevanimibe
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2018 (NCT03669549)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Sterol O-acyltransferase 1INHIBITOR
SOAT1 inhibitor
Acyl coenzyme A:cholesterol acyltransferase 1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)c1cccc(C(C)C)c1NC(=O)NCC1(c2ccc(N(C)C)cc2)CCCC1- Mol. weight
- 421.63 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL46423 ↗
Also known as
- nevanimibe hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03669549 | Phase 2 | Aug 1, 2018 | Millendo Therapeutics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Millendo Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2018 |
1 organizations
Page 1 / 1